Interestingly, based on the clinical characteristics of GBM patients, tumor cells collected from the MGMT-negative patients were also sensitive to Bru treatment at 48h, indicating that Bru successfully inhibited the proliferation of TMZ-resistant human primary GBM cells (case No. 4, 8, 10 in Table 1). The gene discussed is MGMT; the disease is glioblastoma.